https://www.army.mil/article/262786/84_million_contract_awarded_for_excalibur_replenishment
Northland Capital Markets Maintains Outperform on Nabriva Therapeutics. Price Adjusts to $18.
Northland Capital Markets analyst Carl Byrnes maintains Nabriva Therapeutics (NASDAQ:NBRV) with a Outperform. Price Adjusts to $18